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People with mutations in DNA mismatch repair genes have 
a substantial risk of colorectal and other cancers (Vasen et al,
1996; Dunlop et al, 1997; Aarnio et al, 1999; Lynch and de 
La Chappelle, 1999). However, robust estimates of population
carrier frequency are not available because case ascertainment in
most reported studies has been biased towards probands with an
established family history. Although mutation carriers may have
family histories amounting to hereditary nonpolyposis colorectal
cancer (HNPCC), a strong family history of colorectal cancer may
be lacking in a substantial proportion of people with proven muta-
tions (Farrington et al, 1998; Wijnen et al, 1998). Hence, popula-
tion prevalence of mismatch repair gene mutations cannot be
calculated from studies employing family history ascertainment. 
Knowledge of carrier frequency in the population is of consider-
able importance because it informs the application of mutation-
testing strategies as well as defining the contribution of defective
DNA mismatch repair to overall colorectal cancer incidence. Here,
we determined genotype for hMLH1 and hMSH2 for a cohort of
relatives where bias due to family history ascertainment has been
minimized. We incorporated these data and the colorectal cancer
prevalence for mutation carriers in a Bayesian calculation, along with
age-at-onset and mutation data from two systematic series of
colorectal cancer patients from Finland and the USA, in order to esti-
mate population carrier frequency of hMLH1 and hMSH2 mutations. 
METHODS 
We determined the hMLH1 and hMSH2 genotype of all surviving
relatives of Scottish probands with early-onset colorectal cancer,
whose mutations were previously reported by us (Dunlop et al,
1997). These six probands with documented mutations were ascer-
tained on the basis of being affected by colorectal cancer when
aged less than 30 years at diagnosis, irrespective of family history.
Mutation screening was also directed by assessment of tumour
microsatellite instability (Dunlop et al, 1997). Thus, relatives of
these probands comprise a cohort where colorectal cancer preva-
lence is not biased by pre-selection on the basis of a cancer family
history. We defined the pedigrees fully by face-to-face interviews
and a genealogical search of Scottish central records. Colorectal
cancer prevalence was determined for mutation carriers within the
families by combining information obtained at interview and
cancer data from Scottish central records. 
Genotypes for family members were determined from DNA
or RNA purified from peripheral blood leukocytes. hMSH2
and hMLH1 genotypes were determined by DNA sequencing
of PCR products amplified from genomic templates, by speci-
fically designed PCR/restriction digestion assays or by cDNA
sequencing, as appropriate for each respective mutation. Sequenc-
ing was done using an ABI 377 automated sequencer. Sequencing
primers are lodged at: http://www.hgu.mrc.ac.uk/Users/Malcolm.
Dunlop/MMRprim. htm.
To provide estimates of population carrier rates in the age group
15–74 years, we used Bayes’ rule to derive the following expres-
sion for population carrier frequency: 
[(carrier frequency in colorectal cancer patients)
× (population prevalence of colorectal cancer)]/ 
(prevalence of colorectal cancer in carriers) 
Each component of the equation is independent and requires data
that is unbiased by family history status. We restricted analysis to
people aged 15–74 years, in view of surveillance issues and
because population cancer prevalence data outwith this age range
are less robust. 
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together with Scottish National Cancer Registry data were incor-
porated into the expression. Carrier frequency in colorectal cancer
patients was determined by combining hMSH2/hMLH1 mutation
prevalence data and age distribution from systematically collected
cohorts from Finland (Aaltonen et al, 1998) and Baltimore (Liu et
al, 1995). Only patients within the 15–74 year age groups from
these cohorts were included, to accord with the age selection of the
Scottish relatives and population groups. This age restriction is
essential for valid comparison within the Bayesian calculation. A
Medline search did not identify any other systematic studies of
hMSH2 and hMLH1 mutation prevalence in unselected cancer
cohorts. 
The study was subject to local ethical approval by Lothian and
Borders Ethics Committee and to approval by the Multi-Centre
Research Ethics Committee for Scotland. 
RESULTS 
There were 110 surviving family members aged 15–74 years in the
families of five of the probands originally reported by us (Dunlop et
al, 1997). Pedigree analysis for the sixth proband was impossible
due to non-paternity. Probands themselves were excluded, since
they were selected on the basis of having previously developed
cancer. Furthermore, surviving parents or grandparents were also
excluded from the analysis to avoid potential biases of age and
reproductive fitness. There were 48 (44%) relatives aged 15–74
years (mean age = 37.7, SD = 13.0) who carried the same mutation
as the respective proband and 62 relatives (mean age = 42.1, 
SD = 15.0) carried only wild type alleles. Seven mutation carriers
(14.6%) developed colorectal cancer within the 10-year period
ending 1995 (mean age = 46.1, SD = 11.0). Colorectal cancer preva-
lence was calculated from 1995 Scottish population data when there
were 3838547 people aged 15–74 years (mean age = 42.2, 
SD = 16.3) (Registrar General for Scotland, 1998). In all, 6712
(0.17%) of the Scottish population aged 15–74 years, who were
alive in 1995 had developed colorectal cancer within the previous
10 years (mean age = 64.0, SD = 8.9) (Harris et al, 1998). There
were 414 patients aged 15–74 years in the combined
Finnish/Baltimore cohort and 11 (2.66%) had germline hMSH2 or
hMLH1 mutations (Table 1). 
By applying these values as parameters in the formula that we
devised, we estimate that the population carrier frequency is 319
per million (95% CI = 131–802 per million assuming that the
logarithm of the estimate is normally distributed) or 1:3139 of the
population aged 15–74 years. The estimate appears robust because
the age distributions of the Scottish, Finnish and Baltimore cohorts
are very similar, as are the Scottish population and relatives from
the Scottish families whom we established were non-carriers. 
DISCUSSION 
This study provides an estimate of carrier frequency of mutations
in hMLH1 and hMSH2 based on systematically collected data 
that is not subject to bias due to family history ascertainment. By
applying the estimated carrier frequency to demographic data from
the UK (Registrar General for Scotland, 1999; UK Government
Statistical Service, 1999), Finland (Population Statistics Finland,
1999) and the USA (US Bureau of Census, 1999) we estimate that,
pro rata, there are 13925 people, 1228 people and 62845 people
alive in the age group 15–74 years who carry mutations of hMSH2
or hMLH1 in these three populations respectively. It should be
noted that there will be additional mutation carriers within these
populations who are aged less than age 15 years, and a small
number of people aged 75 years or older, but data available to us
would not afford reliable estimates in these age groups. Since the
risk of colorectal and other cancers is very high for gene carriers
(Dunlop et al, 1997), there is substantial rationale in strategies
aimed at presymptomatic carrier detection, so that preventive
measures might be instigated. 
This analysis may underestimate carrier frequency for a number
of reasons. The estimate incorporates data over a time period when
relatives were not offered surveillance and so a proportion
succumbed early to cancer, prior to completing their family.
Surveillance and early detection will reduce this reproductive
disadvantage to carriers and consequently increase carrier
frequency. Underestimation of true carrier rate may also arise as a
consequence of the mutation detection strategy used in the
Scottish, Finnish and Baltimore studies (Liu et al, 1995; Aaltonen
et al, 1998). In each of these cohorts, tumour microsatellite insta-
bility was used to select patients for germline mutation searching.
However, we have previously shown that 14% of hMSH2/hMLH1
carriers (Farrington et al, 1998) have tumours that do not exhibit
microsatellite instability. Furthermore, germline mutations in
another MMR gene, hMSH6, are frequently associated with
tumours that do not exhibit microsatellite instability (Wijnen et al,
1999; Wu et al, 1999). Hence, although useful for targeting
resources, restricting mutation analysis of MMR genes to patients
who have microsatellite-unstable tumours may underestimate
mutation prevalence in any given cancer cohort. Finally, the fami-
lies that are the subject of this analysis were ascertained from
probands who developed colorectal cancer when aged < 30 years
(Dunlop et al, 1997). It is possible that such an extreme phenotype
might be a source of bias towards highly penetrant mutations.
Lower penetrance mutations are likely to be more prevalent. 
Since incorporating all of these confounding factors tends to
increase the estimated carrier frequency, we are confident that
1:3139 is a minimal estimate for the population in the age range
15–74 years. 
We assumed that Finnish and Baltimore data could be applied to
the Scottish population. This seems reasonable since the age distri-
bution and colorectal cancer incidence in the three populations is
similar. Although every population is, to a certain extent, unique,
distortion of the estimate due to differences in the populations
considered here are likely to be trivial. Furthermore, we found that
the age distributions of the Scottish, Finnish and Baltimore cancer
cohorts were also very similar, again supporting the validity of
incorporating data from the three population groups in the
Bayesian calculation. 
The precision of the estimate will improve with ongoing studies
of unselected families. Notwithstanding these qualifications, the
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Table 1 Mutation prevalence and age distribution of cohorts from Finland
and Baltimore used in the analysis 
CRC patients aged 15–74 years 
Number Mean age  SD Carrier % 
(years)
Aaltonen et al 337 62.1 9.7 10 3.0 
Liu et al (Caucasians) 77 60.2 11.3 1 1.3 
Combined 414 61.7 10.1 11 2.7 estimated population carrier frequency presented here suggests
that carrier detection programmes should be incorporated into
strategies aimed at reducing CRC mortality, particularly since
mutation screening costs are decreasing with technological
advances. The lifetime risk of a variety of malignancies for carriers
is around 90% and the risk of colorectal and endometrial cancer is
particularly well documented (Vasen et al, 1996; Dunlop et al,
1997; Aarnio et al, 1999). Hence, targeting surveillance to those
who most need it could make an appreciable impact on reducing
overall cancer mortality.
It is important to note that this estimate of carrier frequency is
restricted to hMLH1 and hMSH2 mutations. Recent data indicate
that mutations of hMSH6 account for an appreciable proportion of
HNPCC-like families (Wijnen et al, 1999) and so there seems to be
a strong case for devising population-based strategies for detection
of germline carriers of mutations in these three mismatch repair
genes, in view of the potential for cancer prevention. 
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